<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318874</url>
  </required_header>
  <id_info>
    <org_study_id>2014/1983</org_study_id>
    <nct_id>NCT03318874</nct_id>
  </id_info>
  <brief_title>Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction</brief_title>
  <official_title>Comparing the Effects of THERA°PEARL Eye Mask (Bausch &amp; Lomb Inc., New York, USA) With the Use of Blephasteam® (Spectrum Thea Pharmaceuticals LTD, Macclesfield, UK).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schepens Eye Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Norwegian Dry Eye Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, randomized controlled study in a Norwegian population with meibomian gland
      dysfunction. Patients will be randomized to one of two groups: THERA°PEARL Eye Mask (Bausch &amp;
      Lomb Inc., New York, USA) or Blephasteam® (Spectrum Thea Pharmaceuticals LTD, Macclesfield,
      UK). All patients will receive Hylo-comod (URSAPHARM Arzneimittel GmbH, Saarbrücken,
      Germany).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear film break-up time</measure>
    <time_frame>Change from baseline at three and six months</time_frame>
    <description>Fluorescein applied to tear film, time measured until tear film breaks up after blink. Range of scale from 1 second and higher, where higher values are considered preferable for the patients. Values under 10 seconds are indicative for dry eye disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Surface Disease Index</measure>
    <time_frame>Change from baseline at three and six months</time_frame>
    <description>Dry Eye Self reported Questionnaire, score ranging from 0-100, where lower values are considered preferable for the patients, indicating less symptoms. Values over 12 are indicative for dry eye disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>McMonnies Questionnaire</measure>
    <time_frame>Change from baseline at three and six months</time_frame>
    <description>Dry Eye Self reported Questionnaire. Index ranges from 0 to 45, where a higher score is regarded as more indicative of dry eye disease. A cut-point of greater than 14.5 is recommended for a dry eye diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface staining Ocular surface staining</measure>
    <time_frame>Change from baseline at three and six months</time_frame>
    <description>Fluorescein applied to tear film, staining scored after the Oxford staining scheme, values ranging from 0-15, lower values are considered better for the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear cytokine levels</measure>
    <time_frame>Change from baseline at three and six months</time_frame>
    <description>Multiplex analysis of tear fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer's test</measure>
    <time_frame>Change from baseline at three and six months</time_frame>
    <description>Measurement of 5 minutes of tear production, values ranging from 0 and higher, where lower values are considered worse for the patient. Values under 5 mm are indicative for dry eye disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meibum Quality</measure>
    <time_frame>Change from baseline at three and six months</time_frame>
    <description>Guidelines based on MGD-report of 2011, values ranging from 0-24, where lower values are considered better for the patient, indicating the quality of the meibum secretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meibum Expressibility</measure>
    <time_frame>Change from baseline at three and six months</time_frame>
    <description>Guidelines based on MGD-report of 2011, values ranging from 0-3, where lower values are considered better for the patient, indicating open meibomian glands.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear osmolarity</measure>
    <time_frame>Change from baseline at three and six months</time_frame>
    <description>Osmolarity measured with TearLab, where values under 300 mOsml/L are considered normal.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Blephasteam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heat delivery device, to be used according to guidelines from manufacturer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THERA°PEARL Eye Mask</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heat delivery device, to be used according to guidelines from manufacturer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blephasteam</intervention_name>
    <description>Steam delivery goggles, once daily</description>
    <arm_group_label>Blephasteam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>THERA°PEARL Eye Mask</intervention_name>
    <description>Heat delivery device, delivering heat to the eyelids, once daily</description>
    <arm_group_label>THERA°PEARL Eye Mask</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hylo-comod</intervention_name>
    <description>Tear substitute containing hyaluronic acid, four times daily</description>
    <arm_group_label>Blephasteam</arm_group_label>
    <arm_group_label>THERA°PEARL Eye Mask</arm_group_label>
    <other_name>Sodium hyaluronate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meibomian Gland Dysfunction

          -  Eligible for heat treatment

          -  Ocular Surface Disease Index (OSDI) &gt;12

          -  Quality or expressibility score ≤20 years old: &gt;1 or &gt;20 years old: ≥1

          -  Non-invasive tear film break-up time (NITBUT) &lt;10 s in at least one eye

          -  Schirmer-1 test &gt;5 mm after 5 min

        Exclusion Criteria:

          -  Glaucoma,

          -  Ocular allergy

          -  Autoimmune disease

          -  Contact lens-wear during study

          -  Current punctal plugging

          -  Pregnant/lactating

          -  Candidate for topical anti-inflammatory

          -  Cicatricial meibomian gland dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tor P Uthiem, MD, Phd.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonatan Olafsson</last_name>
    <phone>+4746915838</phone>
    <email>jonatan.olafsson@medisin.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Norwegian Dry Eye Clinic</name>
      <address>
        <city>Oslo</city>
        <zip>0369</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonatan Olafsson</last_name>
      <phone>+4746915838</phone>
      <email>jonatan.olafsson@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Behzod Tashbayev, M.D.</last_name>
      <phone>+4746572249</phone>
      <email>behzodt@odont.uio.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Jonatan Olafsson</investigator_full_name>
    <investigator_title>Medical Student</investigator_title>
  </responsible_party>
  <keyword>Dry Eye Disease</keyword>
  <keyword>Meibomian Gland Dysfunction</keyword>
  <keyword>Blephasteam</keyword>
  <keyword>THERA°PEARL Eye Mask</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

